Thomas Kimberly M, Maquilan Genevieve, Stojadinovic Strahinja, Medin Paul, Folkert Michael R, Albuquerque Kevin
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Radiation Oncology, Medical Physics and Engineering, University of Texas Southwestern Medical Center, Dallas, TX.
Brachytherapy. 2017 Sep-Oct;16(5):943-948. doi: 10.1016/j.brachy.2017.05.001. Epub 2017 Jun 8.
Brachytherapy (BT) techniques have historically used a two-dimensional nonvolumetric (NV) system involving dose prescribed to a point fixed in space. We compared dosimetric, toxicity, and oncologic outcomes for volumetric planning (3DV) versus CT point-based planning.
Patients treated with external beam radiation therapy and high dose rate (HDR) intracavitary BT were included (n = 71). Patients planned with NV BT treated from 2009 to 2011 (n = 37) were compared to patients planned with 3DV BT treated from 2012 to 2014 (n = 34). Investigators delineated volumes for organs at risk clinical target volumes for the 2009-2011 NV cohort. Acute and chronic toxicity data were graded.
The mean HDR clinical target volume D90 received in the NV and 3DV cohorts were significantly different (p < 0.001). The mean dose to point A was significantly higher in the NV cohort than in the 3DV cohort (p < 0.001). There were significantly more Grade 3 or higher gastrointestinal toxicities in the NV cohort (p = 0.048). There was a nonsignificant trend toward improved oncologic outcomes for patients undergoing CT-based planning.
3DV BT allows for a significant reduction of dose to critical structures, resulting in decreased gastrointestinal toxicity, while delivering noninferior doses to the high-risk clinical target volume. Outcomes were improved in the 3D cohort trending toward statistical significance.
近距离放射治疗(BT)技术在历史上一直使用二维非容积(NV)系统,该系统涉及规定给空间中固定点的剂量。我们比较了容积规划(3DV)与基于CT点的规划的剂量学、毒性和肿瘤学结果。
纳入接受外照射放疗和高剂量率(HDR)腔内BT治疗的患者(n = 71)。将2009年至2011年接受NV BT规划治疗的患者(n = 37)与2012年至2014年接受3DV BT规划治疗的患者(n = 34)进行比较。研究人员为2009 - 2011年NV队列的危及器官和临床靶体积划定了体积。对急性和慢性毒性数据进行分级。
NV队列和3DV队列中接受的平均HDR临床靶体积D90有显著差异(p < 0.001)。NV队列中点A的平均剂量显著高于3DV队列(p < 0.001)。NV队列中3级或更高等级的胃肠道毒性显著更多(p = 0.048)。接受基于CT规划的患者在肿瘤学结果改善方面有不显著的趋势。
3DV BT能够显著降低关键结构的剂量,从而降低胃肠道毒性,同时向高危临床靶体积提供不劣于传统方法的剂量。3D队列中的结果有所改善,有趋向统计学显著性的趋势。